Average Daily Glucocorticoid Dose, Number of Prescription Days, and Cumulative Dose in the Initial 90 days of Glucocorticoid Therapy Are Associated with Subsequent Hip and Clinical Vertebral Fracture Risk: a Retrospective Cohort Study Using A...

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2024 Jan 24

PMID 38267664

Authors

Masayuki Iki

Kenji Fujimori

Shinichi Nakatoh

Junko Tamaki

Shigeyuki Ishii

Nobukazu Okimoto

Hironori Imano

Sumito Ogawa

Affiliations

Soon will be listed here.

Abstract

Purpose: Fracture risk assessment is recommended at three months after glucocorticoid (GC) therapy initiation. This study aimed to assess whether GC exposure in the initial 90 days of GC therapy is associated with subsequent hip and clinical vertebral fracture risk using the nationwide health insurance claims database of Japan (NDBJ).

Methods: Patients aged 50 years who were prescribed GC (≥ 70 mg prednisolone or equivalent; PSL) in the initial 90 days of GC therapy and were followed for hip and clinical vertebral fracture incidences for the subsequent 1080 days were selected from NDBJ. Associations of GC exposure with hip or clinical vertebral fracture risk were evaluated by Cox regression analysis adjusted for potential confounders.

Results: We selected 316,396 women and 299,871 men for the GC-exposed group and 43,164 women and 33,702 men for the reference group. Higher GC doses and longer prescription days in the initial 90 days of GC therapy were significantly and dose-dependently associated with increased fracture risk relative to the reference group. Patients receiving GC 5 mg PSL/day had a significantly increased fracture risk in the stratum of 30-59 days of GC prescription. In addition, female patients who received GC (≥ 1 and < 2.5 mg PSL/day) for 90 days in the initial 90 days of GC therapy had a significantly increased fracture risk.

Conclusions: GC exposure in the initial 90 days of GC therapy was dose-dependently associated with hip and clinical vertebral fracture risk. GC may increase fracture risk with lower doses for shorter durations than previously reported. Fracture risk assessment three months after glucocorticoid (GC) therapy initiation is recommended. We found that GC exposure in the initial 90 days of GC therapy at lower daily doses for shorter durations than previously reported were significantly and dose-dependently associated with fracture risk using a nationwide health insurance claims database.

Citing Articles

Ukrainian guideline for the prevention and treatment of glucocorticoid-induced osteoporosis.

Grygorieva N, Kovalenko V, korzh M, Tronko M, Golovach I, Dedukh N Arch Osteoporos. 2025; 20(1):31.

PMID: 39992470 DOI: 10.1007/s11657-025-01512-9.

Revolutionary Changes in the Management of Lupus Nephritis: Towards De-Glucocorticoid or No-Glucocorticoid.

Tanaka Y Drugs. 2025; .

PMID: 39985741 DOI: 10.1007/s40265-025-02156-2.

Author Response to: Comment from Cheng Gu and Yu Cui on: Rapid reduction in fracture risk after the discontinuation of long-term oral glucocorticoid therapy: a retrospective cohort study using a nationwide health insurance claims database in Japan.

Iki M, Fujimori K, Okimoto N, Nakatoh S, Tamaki J, Ishii S Osteoporos Int. 2024; 36(2):359-360.

PMID: 39656245 DOI: 10.1007/s00198-024-07333-9.

References

Locascio V, Bonucci E, IMBIMBO B, Ballanti P, Adami S, Milani S . Bone loss in response to long-term glucocorticoid therapy. Bone Miner. 1990; 8(1):39-51. DOI: 10.1016/0169-6009(91)90139-q. View

Laan R, van Riel P, van de Putte L, van Erning L, vant Hof M, Lemmens J . Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med. 1993; 119(10):963-8. DOI: 10.7326/0003-4819-119-10-199311150-00001. View

Steinbuch M, Youket T, Cohen S . Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int. 2004; 15(4):323-8. DOI: 10.1007/s00198-003-1548-3. View

Kanis J, Johansson H, Oden A, Johnell O, De Laet C, Melton Iii L . A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004; 19(6):893-9. DOI: 10.1359/JBMR.040134. View

van Staa T, Leufkens H, Cooper C . The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002; 13(10):777-87. DOI: 10.1007/s001980200108. View

Cauley J, Thompson D, Ensrud K, Scott J, Black D . Risk of mortality following clinical fractures. Osteoporos Int. 2000; 11(7):556-61. DOI: 10.1007/s001980070075. View

Peeters C, Visser E, van de Ree C, Gosens T, Den Oudsten B, de Vries J . Quality of life after hip fracture in the elderly: A systematic literature review. Injury. 2016; 47(7):1369-82. DOI: 10.1016/j.injury.2016.04.018. View

Buckley L, Humphrey M . Glucocorticoid-Induced Osteoporosis. N Engl J Med. 2018; 379(26):2547-2556. DOI: 10.1056/NEJMcp1800214. View

Chotiyarnwong P, McCloskey E . Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat Rev Endocrinol. 2020; 16(8):437-447. DOI: 10.1038/s41574-020-0341-0. View

10.

Lee T, Song Y, Kim H, Sung Y, Cho S . Intervention Thresholds for Treatment in Patients with Glucocorticoid-Induced Osteoporosis: Systematic Review of Guidelines. J Bone Metab. 2020; 27(4):247-259. PMC: 7746480. DOI: 10.11005/jbm.2020.27.4.247. View

11.

Buckley L, Guyatt G, Fink H, Cannon M, Grossman J, Hansen K . 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2017; 69(8):1521-1537. DOI: 10.1002/art.40137. View

12.

Suzuki Y, Nawata H, Soen S, Fujiwara S, Nakayama H, Tanaka I . Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J Bone Miner Metab. 2014; 32(4):337-50. DOI: 10.1007/s00774-014-0586-6. View

13.

Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N . UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017; 12(1):43. PMC: 5397452. DOI: 10.1007/s11657-017-0324-5. View

14.

Hoes J, Jacobs J, Boers M, Boumpas D, Buttgereit F, Caeyers N . EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007; 66(12):1560-7. PMC: 2095301. DOI: 10.1136/ard.2007.072157. View

15.

Lekamwasam S, Adachi J, Agnusdei D, Bilezikian J, Boonen S, Borgstrom F . A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int. 2012; 23(9):2257-76. DOI: 10.1007/s00198-012-1958-1. View

16.

Amiche M, Abtahi S, Driessen J, Vestergaard P, de Vries F, Cadarette S . Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study. Arch Osteoporos. 2018; 13(1):30. PMC: 5857556. DOI: 10.1007/s11657-018-0424-x. View

17.

Bours S, de Vries F, van den Bergh J, Lalmohamed A, van Staa T, Leufkens H . Risk of vertebral and non-vertebral fractures in patients with sarcoidosis: a population-based cohort. Osteoporos Int. 2015; 27(4):1603-1610. PMC: 4791462. DOI: 10.1007/s00198-015-3426-1. View

18.

Kim D, Cho S, Park B, Jang E, Bae S, Sung Y . Glucocorticoids Are Associated with an Increased Risk for Vertebral Fracture in Patients with Rheumatoid Arthritis. J Rheumatol. 2018; 45(5):612-620. DOI: 10.3899/jrheum.170054. View

19.

Lee E, Lee M, Park B, Park I . Risk of fracture according to glucocorticoid use after renal biopsy: a nationwide population-based study. Sci Rep. 2020; 10(1):13846. PMC: 7429855. DOI: 10.1038/s41598-020-70935-w. View

20.

Robinson D, van Staa T, Dennison E, Cooper C, Dixon W . The limitations of using simple definitions of glucocorticoid exposure to predict fracture risk: A cohort study. Bone. 2018; 117:83-90. PMC: 6173307. DOI: 10.1016/j.bone.2018.09.004. View